Pharmaceutical Executive March 24, 2022
Pharmaceutical Executive Editorial Staff

Genomic data is transforming precision medicine—but progress depends on it being easily available where it’s needed. Pharmaceutical Executive speaks to Ignacio Medina, founder of Cambridge University spinout Zetta Genomics, to see how next-generation open-source data technologies accelerate discovery in the lab and patient benefit in the clinic.

Pharm Exec: What inspired you to found Zetta Genomics—what is the problem you solve?

Medina: In the decade following the mapping of the human genome, genomics was something of a cottage industry: low volume, highly specialized, and time intensive. This all changed in 2013 with Genomics England’s 100,000 Genomes Project. The ask was significant: to not only sequence and analyze an unprecedented number of genomes, but also to build the infrastructure and design...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Interview / Q&A, Pharma / Biotech, Precision Medicine, Trends
Putting Patients First by Extending the Reach of World-Class Care
Healthcare's most promising tech
AI In Healthcare: A New Era Of Personalized Patient Care
23andMe reports sales decline a day after announcing plans to cut 40% of workforce
Patient-derived organoids: Transforming cancer research and personalized medicine

Share This Article